India, Nov. 19 -- The U.S. FDA has granted Rare Pediatric Disease Designation to Medivir AB(MVIR.ST)investigational drug MIV-711 for osteogenesis imperfecta (OI), also known as brittle bone disease, a rare inherited condition that causes fragile bones and frequent fractures. MIV-711 blocks cathepsin K, an enzyme involved in bone breakdown.
Preclinical studies showed dose-dependent improvements in bone strength, quality and structure. The drug already holds Orphan Drug Designation for OI. Medivir plans to begin a proof-of-concept clinical study, supported by secured funding.
If eventually approved, MIV-711 may qualify for a transferable FDA Priority Review Voucher.
Currently, MVIR.ST is trading at SEK1.14, up 4.59%
For comments and feedb...